Original Publication Date: 25 January, 2016
Publication / Source: Immunotherapy
Authors: David Allard, Bertrand Allard, Pierre-Olivier Gaudreau, Pavel Chrobak & John Stagg
Cancer immunotherapy has entered in a new era with the development of first-generation immune checkpoint inhibitors targeting the PD1/PD-L1 and CTLA-4 pathways. In this context, considerable research effort is being deployed to find the next generation of cancer immunotherapeutics. The CD73–adenosine axis constitutes one of the most promising pathways in immuno-oncology.